🚀 VC round data is live in beta, check it out!
Annovis Bio Valuation Multiples
Discover revenue and EBITDA valuation multiples for Annovis Bio and similar public comparables like Vivoryon Therapeutics, Corestemchemon, Lisata Therapeutics, Corline Biomedical and more.
Annovis Bio Overview
About Annovis Bio
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
Founded
2008
HQ
Employees
8
Website
Sectors
Financials (LTM)
EV
$26M
Annovis Bio Financials
Annovis Bio reported last 12-month revenue of — and negative EBITDA of ($33M).
In the same LTM period, Annovis Bio generated — in gross profit, ($33M) in EBITDA losses, and had net loss of ($33M).
Revenue (LTM)
Annovis Bio P&L
In the most recent fiscal year, Annovis Bio reported revenue of — and EBITDA of ($30M).
Annovis Bio expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | ($33M) | XXX | ($30M) | XXX | XXX | XXX |
| Net Profit | ($33M) | XXX | ($29M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Annovis Bio Stock Performance
Annovis Bio has current market cap of $46M, and enterprise value of $26M.
Market Cap Evolution
Annovis Bio's stock price is $1.62.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26M | $46M | -29.6% | XXX | XXX | XXX | $-1.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAnnovis Bio Valuation Multiples
Annovis Bio trades at (0.8x) EV/EBITDA.
Annovis Bio Financial Valuation Multiples
As of April 11, 2026, Annovis Bio has market cap of $46M and EV of $26M.
Equity research analysts estimate Annovis Bio's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Annovis Bio has a P/E ratio of (1.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $46M | XXX | $46M | XXX | XXX | XXX |
| EV (current) | $26M | XXX | $26M | XXX | XXX | XXX |
| EV/EBITDA | (0.8x) | XXX | (0.9x) | XXX | XXX | XXX |
| EV/EBIT | (0.8x) | XXX | (0.9x) | XXX | XXX | XXX |
| P/E | (1.4x) | XXX | (1.6x) | XXX | XXX | XXX |
| EV/FCF | (0.9x) | XXX | (1.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Annovis Bio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Annovis Bio Margins & Growth Rates
Annovis Bio's revenue in the last fiscal year grew by —.
Annovis Bio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $3.7M for the same period.
Annovis Bio Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA Growth | 54% | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $3.7M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Annovis Bio Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Corestemchemon | XXX | XXX | XXX | XXX | XXX | XXX |
| Lisata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Corline Biomedical | XXX | XXX | XXX | XXX | XXX | XXX |
| Zhengye Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Annovis Bio M&A Activity
Annovis Bio acquired XXX companies to date.
Last acquisition by Annovis Bio was on XXXXXXXX, XXXXX. Annovis Bio acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Annovis Bio
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAnnovis Bio Investment Activity
Annovis Bio invested in XXX companies to date.
Annovis Bio made its latest investment on XXXXXXXX, XXXXX. Annovis Bio invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Annovis Bio
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Annovis Bio
| When was Annovis Bio founded? | Annovis Bio was founded in 2008. |
| Where is Annovis Bio headquartered? | Annovis Bio is headquartered in United States. |
| How many employees does Annovis Bio have? | As of today, Annovis Bio has over 8 employees. |
| Who is the CEO of Annovis Bio? | Annovis Bio's CEO is Maria Maccecchini. |
| Is Annovis Bio publicly listed? | Yes, Annovis Bio is a public company listed on NYSE. |
| What is the stock symbol of Annovis Bio? | Annovis Bio trades under ANVS ticker. |
| When did Annovis Bio go public? | Annovis Bio went public in 2020. |
| Who are competitors of Annovis Bio? | Annovis Bio main competitors are Vivoryon Therapeutics, Corestemchemon, Lisata Therapeutics, Corline Biomedical. |
| What is the current market cap of Annovis Bio? | Annovis Bio's current market cap is $46M. |
| Is Annovis Bio profitable? | No, Annovis Bio is not profitable. |
| What is the current EBITDA of Annovis Bio? | Annovis Bio has negative EBITDA and is not profitable. |
| What is the current EV/EBITDA multiple of Annovis Bio? | Current EBITDA multiple of Annovis Bio is (0.8x). |
| What is the current FCF of Annovis Bio? | Annovis Bio's last 12 months FCF is ($29M). |
| What is the current EV/FCF multiple of Annovis Bio? | Current FCF multiple of Annovis Bio is (0.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.